Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01021514

Enrollment

Registered

2009-11-30

Start date

2009-01-31

Completion date

2010-11-30

Last updated

2011-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sRAGE Level, SUV and TBR Levels in FDG PET

Keywords

sRAGE, SUV, TBR, FDG PET CT, Type 2 DM

Brief summary

Arteriosclerosis is a dynamic inflammatory disorder. Recently, FDG-PET CT is emerging diagnostic tool of non-invasive technique to detect vulnerable atherosclerotic plaque. And there are arising evidence that sRAGE(soluble Receptor for Advanced glycation End Product) is correlated with metabolic risk. So the investigators will investigate association between sRAGE and FDG-PET uptake in large artery in healthy patient.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

16 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis od type 2 DM

Exclusion criteria

* Type 1 DM * Gestational Diabetes * Severe Liver or Renal disease * Diagnosis of cancer * Trauma * Acute infection or inflammatory disease * Acute vasculitis or history of vasculitis * Pregnant or Lactating women * Dyslipidemia(active state) * Cardiovascular disease or history of CVD * Chronic obstructive pulmonary disease * Any patient by judge of investigator

Outcome results